Duke spinoff Aerie Pharmaceuticals is looking for $15 million in debt financing, according to a security filing. Aerie has been developing a glaucoma treatment and netted positive results last month for a Phase 2a study of its once-daily eye drop treatment. The company, which netted more than $41 million in an equity round last year, has raised $3 million so far in its latest debt round with $12 million left to go. The first sale happened earlier this month. According to the filing, the financing comes with the option to acquire another security. Five investors have participated so far and, according to the filing, $1.3 million of the offering is being proposed to be used for payments of executive officers, directors or promoters.
